205 articles, find any in seconds
Browse the reference
·
11 disciplines · 205 articles
Data Integrity ALCOA+, audit trails, the data lifecycle, program architecture, and warning-letter patterns. 28
- B Breaking Into GxP Quality: A Learning Roadmap From Zero to Employed ->
- B Breaking Into GxP: A Realistic Career Guide for Validation and Quality ->
- B Data Integrity in Pharma: What It Is and Why It Keeps Failing ->
- B Good Documentation Practices: The Mechanics Under ALCOA+ ->
- B The GxP, CSV, and Data Integrity Glossary: Every Acronym Decoded ->
- I ALCOA+: The Framework Behind Every Data Integrity Requirement ->
- I Audit Trail Design and Review: What Inspectors Actually Expect ->
- I Building a GxP Data Flow Map ->
- I Clinical Quality Assurance: GCP Data Integrity and EDC System Validation ->
- I Data Criticality and Data Risk: Classifying Records to Right-Size Controls ->
- I Data Governance Roles and Career Paths: Owner, Steward, Custodian, and the Digital Quality Function ->
- I Hybrid Systems: Managing Paper-and-Electronic Records Without Breaking ALCOA+ ->
- I Second-Person Review of Analytical and QC Laboratory Data ->
- I Static vs Dynamic Records, True Copies, and Source Data Verification ->
- I The Data Lifecycle in GxP: From Generation to Archival ->
- I Time Stamps, NTP Synchronization, and Time-Zone Control in GxP Systems ->
- A BLA Readiness: Building and Defending the CMC Data Package ->
- A Building a Data Governance Framework for GxP Operations ->
- A Building a Data Integrity Program: Architecture, Governance, and the Gap Assessment ->
- A Chromatography Data System Integrity: Injection Sequences, Integration, and the Reprocessing Trap ->
- A Data Integrity Gap Assessment: A Methodology That Actually Finds Something ->
- A Data Integrity in the Microbiology QC Laboratory ->
- A Data Integrity Self-Audit: A Compliance Checklist for GxP Organizations ->
- A FDA Data Integrity Warning Letters: 8 Patterns That Repeat ->
- A Investigating a Data Integrity Breach or Suspected Falsification ->
- A Operationalizing Audit Trail Review: Risk-Based and Review-by-Exception Approaches ->
- A Quality Culture and Data Integrity Failures: The Behavioral Science Behind Why People Falsify Data ->
- A Running a Data Integrity Remediation Program: From Warning Letter to Sustainable Compliance ->
CSV / CSA GAMP 5, the validation lifecycle, the CSA risk-based approach, cloud and SaaS. 34
- B GxP Computerized Systems: LIMS, CDS, ELN, MES, CTMS, and More, A Complete Map ->
- I 21 CFR Part 11 and EU Annex 11: A Practical Assessment Guide ->
- I 21 CFR Part 11 and EU Annex 11: Electronic Records and Signatures Explained ->
- I Backup, Restore, and Disaster Recovery Validation for GxP Systems ->
- I Change Control for Validated Systems: What Triggers Revalidation and How to Manage It ->
- I CSV Risk Assessment: How to Scope and Execute Risk-Based Validation ->
- I GAMP 5 Second Edition: The Framework for Risk-Based Computer System Validation ->
- I Implementing Compliant Electronic Signatures: Binding, Manifestation, and Re-Authentication ->
- I IT Change and Configuration Management for GxP: Bridging ITIL and Validation ->
- I IT Infrastructure Qualification and Spreadsheet Validation ->
- I Managing Test Failures During Validation: Discrepancies, Deviations, and Retests ->
- I Operating Validated GxP Computerized Systems: What Happens After Go-Live ->
- I Project-Managing a Validation: Planning, Resourcing, and Delivering CSV and Qualification on Time ->
- I Reusing Supplier Documentation: Vendor Audits and Software Supplier Assessment ->
- I Supplier and Vendor Collaboration for AI in a GxP Context ->
- I The GxP Computerized System Inventory and Classification ->
- I The GxP Validation Deliverable Set: What Each Document Is Actually For ->
- I The Validation Master Plan and Computerized System Periodic Review ->
- I The Validation Summary Report and the System Release Decision ->
- I User Requirements, Functional/Design Specs, and the Traceability Matrix ->
- I Writing Validation Protocols and Reports: Test Scripts, Acceptance Criteria, and Deviations ->
- A CSV/CSA Self-Audit: Evaluating Your Computer System Validation Program ->
- A Cybersecurity and Access Control for Validated GxP Systems ->
- A Data Migration Validation: Moving GxP Records Without Losing Integrity ->
- A Database-Layer Data Integrity and DBA Governance ->
- A FDA Computer Software Assurance: What Changed and What Didn't ->
- A IEC 62304 and the SaMD Lifecycle for Pharma and Combination Products ->
- A Retroactive Validation and Legacy Systems: What to Do When GxP Systems Were Never Properly Validated ->
- A Security Event Logging, Monitoring, and Review for GxP Systems ->
- A Software as a Medical Device in Pharma and Combination Products: FDA Premarket Expectations, Cybersecurity, and the Product Lifecycle ->
- A System Decommissioning, Data Archival, and Lawful Retention ->
- A Validating Agile and DevOps-Delivered GxP Software: CI/CD in a Regulated World ->
- A Validating Cloud and SaaS Systems in GxP: The Shared Responsibility Model ->
- A Validating Custom Software: GAMP Category 5 from Specification to Release ->
Quality Assurance The pharmaceutical quality system, CAPA, deviations, change control, validation, and document control. 52
- B 21 CFR 210 and 211 Walkthrough: The US cGMP Regulation Subpart by Subpart ->
- B Certificate of Analysis and Certificate of Compliance: Reading, Issuing, and Verifying ->
- B Deviation Management in GxP: Classification, Investigation, and Resolution ->
- B Document Control in GxP: How Controlled Documents Actually Work ->
- B GxP Roles Explained: Who Does What in a Regulated Biotech or Pharma Company ->
- B How to Write an SOP People Actually Follow: Structure, Language, and Common Failures ->
- B Interview Preparation for GxP Quality, CSV, and Validation Roles ->
- B The Quality Manual and QMS Document Hierarchy: Policies, SOPs, Work Instructions, and Records ->
- B What Is a CAPA? Corrective and Preventive Action Explained ->
- B What Is GMP? A Plain-Language Introduction to Good Manufacturing Practice ->
- B Why Validation Matters: Proving That Systems and Processes Actually Work ->
- I Annual Product Review and the Product Quality Review (PQR) ->
- I Batch Disposition: How Release, Reject, and Quarantine Decisions Get Made ->
- I Batch Record Review: What It Is, What to Look For, and What Regulators Expect ->
- I CAPA Effectiveness Checks: Designing Verification That Proves the Fix Worked ->
- I CDMO Oversight and Quality Agreements ->
- I Cleaning Validation in Pharmaceutical Manufacturing: ADE, PDE, and the Full Framework ->
- I Clinical Systems and GCP Digital Quality: EDC, IRT, eTMF, and CTMS ->
- I Combination Products: cGMP Compliance Under 21 CFR Part 4 ->
- I Cross-Contamination Control in Shared Facilities: Dedicated Equipment, Campaigning, and HBELs ->
- I GxP Training Program Design: Building a System That Actually Changes Behavior ->
- I ICH Q10: The Pharmaceutical Quality System Framework ->
- I ICH Q7: GMP for Active Pharmaceutical Ingredients ->
- I IND, NDA, and BLA: US Regulatory Pathways From First-in-Human to Approval ->
- I Management Review: Running the Meeting That Proves the Quality System Works ->
- I OOS Investigations: The Step-by-Step Process FDA Expects ->
- I Out-of-Trend (OOT) Results: Detection, Statistical Triggers, and Investigation ->
- I Product Complaint Handling: Intake, Investigation, Trending, and Regulatory Reporting ->
- I QMS Self-Audit: Evaluating Your Pharmaceutical Quality Management System ->
- I Quality Metrics and KPIs: Building a Dashboard Inspectors and Executives Both Trust ->
- I Quality Risk Management: ICH Q9(R1), FMEA, and Risk-Based Decision Making in GxP ->
- I Root Cause Analysis in GxP: 5 Whys, Fishbone, Fault Tree, and How to Pick One ->
- I Stability Programs in Pharmaceutical QA: ICH Q1A Through Q1F in Practice ->
- I Statistics in QA: Sampling, Process Capability, Control Charts, and OOT ->
- I Supplier and Vendor Qualification in GxP: From Approved Vendor List to Audit ->
- I Technical Writing for GxP: Protocols, Reports, Deviations, and Defensible Documentation ->
- I Triaging Quality Events: Critical, Major, Minor Classification and Risk Ranking ->
- I When Human Error Is Not a Root Cause: Investigating and Preventing Repeat Deviations ->
- A Analytical Procedure Lifecycle: ICH Q14 and Q2(R2) ->
- A Cleaning Validation Execution: Swab and Rinse Sampling, Recovery Studies, MACO, and TOC ->
- A Continued Process Verification: Building a Stage 3 CPV Program ->
- A Extractables and Leachables: Assessing What Migrates Into a Product ->
- A ICH Q12: Product Lifecycle Management and Established Conditions ->
- A Impurities and Nitrosamines: ICH Q3, M7, and Risk-Based Control ->
- A Process Validation for Biologics: Viral Clearance, Resin Lifetime, and Column Studies ->
- A Process Validation Lifecycle: Stage 1, 2, and 3 Under ICH Q8/Q9/Q10 ->
- A Qualified Person Certification and EU Batch Release: Annex 16 in Practice ->
- A Quality by Design and Design of Experiments: CQAs, CPPs, and the Design Space ->
- A Quality in Technology Transfer: Site-to-Site, R&D-to-GMP, and the Transfer Protocol ->
- A Recalls and Field Alerts: Classification, Execution, and Effectiveness ->
- A The eCTD and Regulatory Submission Architecture: Modules 1 to 5 and Data Integrity in Filings ->
- A The PPQ Protocol: Designing and Executing Stage 2 Process Performance Qualification ->
Audits & Inspection Inspection readiness, 483 and warning-letter responses, internal audits, FDA vs EMA dynamics. 13
- I Audit Finding Classification: Critical, Major, Minor and the Evidence Behind Each ->
- I FDA Inspection Readiness: Building and Maintaining a State of Control ->
- I How to Conduct a Supplier or GMP Audit: Planning, Agenda, Observations, and the Report ->
- I Internal Audit Program: Planning, Executing, and Following Up ->
- I Regulatory Intelligence: Mining 483s, Warning Letters, and EIRs to Stay Ahead ->
- I Regulatory Reporting Obligations and Their Clocks ->
- I Running a Mock Inspection: Designing a Dry Run That Surfaces Real Gaps ->
- A FDA 483 and Warning Letter Responses: Strategy, Structure, and What Actually Works ->
- A FDA Form 483 and Warning Letters: How to Respond Effectively ->
- A FDA vs. EMA Inspections: Strategic Differences Every Compliance Leader Should Know ->
- A Inspection Readiness: How to Demonstrate a Genuine State of Control ->
- A Managing a Live FDA or EMA Inspection: Front Room, Back Room, Scribes, and SME Conduct ->
- A Managing Health Authority Interactions: Pre-IND, Type A/B/C Meetings, and Information Requests ->
Equipment Qualification DQ/IQ/OQ/PQ, USP <1058>, analytical instrument qualification, method validation and transfer. 14
- I Analytical Instrument Qualification: USP <1058> and the 4Qs Framework ->
- I Analytical Method Validation: ICH Q2(R2) in Practice ->
- I Calibration and Metrology Programs in GMP: Tolerances, Traceability, and Out-of-Tolerance Handling ->
- I Compendial Method Verification: USP <1226> and When Validation Is Not Required ->
- I Equipment and Instrument Qualification Audit Checklist ->
- I Equipment Qualification: DQ, IQ, OQ, PQ, What Each Phase Actually Proves ->
- I Factory and Site Acceptance Testing: FAT and SAT in Equipment Delivery ->
- I Requalification and Periodic Review of Qualified Equipment ->
- I Temperature Mapping and Thermal Qualification of Chambers, Autoclaves, and Cold Storage ->
- A Analytical Method Transfer: Protocol Design, Acceptance Criteria, and Regulatory Filing ->
- A Bioassay and ELISA Validation: Potency, Parallelism, and Relative Standard Curves ->
- A Clean Utilities Qualification: Clean Steam, Compressed Gases, and HVAC ->
- A Commissioning and Qualification the ASTM E2500 Way: Verification, SMEs, and the Science-Based Approach ->
- A Executing Method Validation: Specificity, Linearity, Accuracy, Precision, and Robustness ->
Manufacturing Automation MES, EBR, SCADA, DCS, PLC, and data integrity on the shop floor. 8
- I GxP Manufacturing and Laboratory Systems: MES, SCADA, LIMS, CDS, and ELN ->
- I MES, EBR, SCADA, and the Shop Floor: Data Integrity in Manufacturing Automation ->
- I PLC, DCS, and HMI Fundamentals for Quality and Validation Professionals ->
- I Process Historians and Time-Series Data Integrity ->
- A Automation Systems Validation: PLC, SCADA, DCS, and Interface Controls ->
- A Digital Twins Across the Process Lifecycle ->
- A LIMS Implementation and Validation: Configuration, Workflows, and the Sample Lifecycle ->
- A Recipe Management and Batch Control: ISA-88 (S88) in Validated Manufacturing ->
Sterility & Microbiology EU GMP Annex 1, contamination control strategy, aseptic processing, environmental monitoring. 14
- I Bioburden and Bacterial Endotoxin Testing: USP <61>/<62> and <85> LAL Methods ->
- I Cleanroom Classification and Qualification: ISO 14644, Grade A-D, and Recovery Testing ->
- I Designing an Environmental Monitoring Program for Sterile Manufacturing ->
- I Disinfectant and Sporicidal Efficacy Qualification ->
- I Microbial Identification, Excursions, and the EM Data Trend ->
- I Sterility Testing: USP <71>, Membrane Filtration, and Method Suitability ->
- I Visual Inspection and Particulate Control for Injectables: USP <790> and <788> ->
- A Aseptic Processing and Aseptic Process Simulations (Media Fills) ->
- A Container Closure Integrity Testing: Deterministic Methods and Annex 1 Expectations ->
- A Depyrogenation and Dry Heat Sterilization: Endotoxin Challenge and Validation ->
- A EU GMP Annex 1 and the Contamination Control Strategy ->
- A Pharmaceutical Water System Validation: USP <1231>, WFI, and the Three-Phase Qualification ->
- A Sterilization Validation: Moist Heat, Overkill vs Bioburden, F0, and Biological Indicators ->
- A Sterilizing-Grade Filtration Validation ->
Clinical & GCP GCP data integrity, EDC/eTMF/IRT systems, and safety/pharmacovigilance data. 15
- B Source Data, SDV, and ALCOA in Clinical Trials: Getting the Site Records Right ->
- I Clinical Data Management: EDC Build, Edit Checks, Database Lock, and CDISC Standards ->
- I eConsent and Decentralized Trial Technology: Validation and Part 11 Compliance ->
- I GMP for Investigational Medicinal Products: Phase-Appropriate Quality and IMP Release ->
- I Good Laboratory Practice (21 CFR 58) for Nonclinical Safety Studies ->
- I ICH E6(R2)/E6(R3) Good Clinical Practice: The Foundation of Clinical Trial Quality ->
- I ICH E8(R1) and E9: Quality by Design and Statistical Principles in Clinical Trials ->
- I Pharmacovigilance and Safety Data: GVP and Data Integrity After Approval ->
- I Protocol Deviation Management in Clinical Trials ->
- I Risk-Based and Centralized Monitoring of Clinical Trials ->
- I The Trial Master File: eTMF Structure, the DIA Reference Model, and Inspection Readiness ->
- A Clinical Statistical Programming and TLF Validation ->
- A GCP Audits and Regulatory Inspections: Sponsor, Site, and Vendor Audit Programs ->
- A Maintaining the Blind and Controlling Unblinding ->
- A Sponsor Oversight of CROs and Vendors ->
Supply Chain & GDP Good Distribution Practice, cold chain, serialization, and CDMO oversight. 4
- I Cold Chain Qualification: Temperature Mapping, Shipper Validation, and Excursion Management ->
- I DSCSA and Serialization: Track-and-Trace, EPCIS, and Interoperability ->
- I Good Distribution Practice, Cold Chain, and Serialization ->
- A Data Integrity Across the Supply Chain: Distribution Records, IoT Loggers, and 3PL Oversight ->
Cell & Gene Therapy Why data integrity is structurally different for living, patient-specific products. 4
- I Cell & Gene Therapy: Why Data Integrity Is Structurally Different ->
- A Comparability and Potency Assays for Biologics and Cell & Gene Therapies ->
- A Data Integrity in Gene Therapy: What FDA Really Expects ->
- A GMP for Cell and Gene Therapies: Chain of Identity, Chain of Custody, and ATMP Controls ->
AI & Automation Validating AI-enabled GxP systems and building compliant automation tools. 19
- I AI in Regulatory Affairs and CMC: From Tools to Submission-Ready Governance ->
- I AI Model Credibility and Trust: Earning the Right to Rely on a Model ->
- I AI Risk Assessment for GxP Systems: Sizing the Effort to the Real Risk ->
- I Building AI Tools for GxP: What Actually Works ->
- I Data Readiness for AI in Manufacturing and Quality Operations ->
- I Inspection Readiness for AI-Enabled GxP Systems ->
- I The EU AI Act and Life Sciences: Scope, Risk Tiers, and GxP Overlap ->
- I Using Generative AI in Deviation, CAPA, and Investigation Workflows ->
- I Validating RPA and Workflow Automation in Quality Operations ->
- I Validating Scripts, Notebooks, and Low-Code Analytics (Python, R, Power BI) in GxP ->
- I Workforce and Organizational Readiness for AI in Quality ->
- A AI Governance for GxP: Policy, Roles, and Lifecycle Oversight ->
- A AI in Pharmacovigilance: Validating the Machines That Read Safety Data ->
- A AI/ML in Regulated Drug and Biologic Software: Change Control and Regulatory Expectations ->
- A Managing the GxP Machine Learning Lifecycle: Drift, Retraining, and Continuous Monitoring ->
- A Qualifying Large Language Models and Generative AI for Regulated Use ->
- A Scaling AI from Pilot to Validated Production ->
- A Validating AI-Based Automated Visual Inspection of Injectables ->
- A Validating AI-Enabled GxP Systems: A Framework Still Being Built ->
No topics match. Try a broader term, an acronym, or a regulation number.